Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Refined efficacy estimates of the Sanofi Pasteur dengue vaccine CYD-TDV using machine learning.

Dorigatti I, Donnelly CA, Laydon DJ, Small R, Jackson N, Coudeville L, Ferguson NM.

Nat Commun. 2018 Sep 7;9(1):3644. doi: 10.1038/s41467-018-06006-6.

2.

The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study.

Flasche S, Jit M, Rodríguez-Barraquer I, Coudeville L, Recker M, Koelle K, Milne G, Hladish TJ, Perkins TA, Cummings DA, Dorigatti I, Laydon DJ, España G, Kelso J, Longini I, Lourenco J, Pearson CA, Reiner RC, Mier-Y-Terán-Romero L, Vannice K, Ferguson N.

PLoS Med. 2016 Nov 29;13(11):e1002181. doi: 10.1371/journal.pmed.1002181. eCollection 2016 Nov.

3.

Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment.

Ferguson NM, Rodríguez-Barraquer I, Dorigatti I, Mier-Y-Teran-Romero L, Laydon DJ, Cummings DA.

Science. 2016 Sep 2;353(6303):1033-1036.

4.

Rapid dissemination of human T-lymphotropic virus type 1 during primary infection in transplant recipients.

Cook LB, Melamed A, Demontis MA, Laydon DJ, Fox JM, Tosswill JH, de Freitas D, Price AD, Medcalf JF, Martin F, Neuberger JM, Bangham CR, Taylor GP.

Retrovirology. 2016 Jan 8;13:3. doi: 10.1186/s12977-015-0236-7.

5.

HTLV-1 drives vigorous clonal expansion of infected CD8(+) T cells in natural infection.

Melamed A, Laydon DJ, Al Khatib H, Rowan AG, Taylor GP, Bangham CR.

Retrovirology. 2015 Nov 9;12:91. doi: 10.1186/s12977-015-0221-1.

6.

Estimating T-cell repertoire diversity: limitations of classical estimators and a new approach.

Laydon DJ, Bangham CR, Asquith B.

Philos Trans R Soc Lond B Biol Sci. 2015 Aug 19;370(1675). pii: 20140291. doi: 10.1098/rstb.2014.0291. Review.

7.

HTLV-1 proviral integration sites differ between asymptomatic carriers and patients with HAM/TSP.

Niederer HA, Laydon DJ, Melamed A, Elemans M, Asquith B, Matsuoka M, Bangham CR.

Virol J. 2014 Sep 30;11:172. doi: 10.1186/1743-422X-11-172.

8.

Quantification of HTLV-1 clonality and TCR diversity.

Laydon DJ, Melamed A, Sim A, Gillet NA, Sim K, Darko S, Kroll JS, Douek DC, Price DA, Bangham CR, Asquith B.

PLoS Comput Biol. 2014 Jun 19;10(6):e1003646. doi: 10.1371/journal.pcbi.1003646. eCollection 2014 Jun.

9.

Clonality of HTLV-2 in natural infection.

Melamed A, Witkover AD, Laydon DJ, Brown R, Ladell K, Miners K, Rowan AG, Gormley N, Price DA, Taylor GP, Murphy EL, Bangham CR.

PLoS Pathog. 2014 Mar 13;10(3):e1004006. doi: 10.1371/journal.ppat.1004006. eCollection 2014 Mar.

10.

Strongyloidiasis and infective dermatitis alter human T lymphotropic virus-1 clonality in vivo.

Gillet NA, Cook L, Laydon DJ, Hlela C, Verdonck K, Alvarez C, Gotuzzo E, Clark D, Farré L, Bittencourt A, Asquith B, Taylor GP, Bangham CR.

PLoS Pathog. 2013;9(4):e1003263. doi: 10.1371/journal.ppat.1003263. Epub 2013 Apr 4.

11.

Genome-wide determinants of proviral targeting, clonal abundance and expression in natural HTLV-1 infection.

Melamed A, Laydon DJ, Gillet NA, Tanaka Y, Taylor GP, Bangham CR.

PLoS Pathog. 2013 Mar;9(3):e1003271. doi: 10.1371/journal.ppat.1003271. Epub 2013 Mar 21.

12.

Pre-morbid human T-lymphotropic virus type I proviral load, rather than percentage of abnormal lymphocytes, is associated with an increased risk of aggressive adult T-cell leukemia/lymphoma.

Hodson A, Laydon DJ, Bain BJ, Fields PA, Taylor GP.

Haematologica. 2013 Mar;98(3):385-8. doi: 10.3324/haematol.2012.069476. Epub 2012 Aug 8.

Supplemental Content

Loading ...
Support Center